Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-EU says AstraZeneca under no UK obligation that would prevent EU vaccine supply

Tue, 30th Mar 2021 15:25

(adds AstraZeneca comment)

BRUSSELS, March 30 (Reuters) - AstraZeneca has told
the European Union that it has no legal obligations to Britain
or other buyers that would prevent the full supply of COVID-19
doses under its contract with the EU, a European Commission
spokeswoman said on Tuesday.

Her comments at a news conference contradict statements made
by British Health Minister Matt Hancock, who has repeatedly said
the Anglo-Swedish firm has an exclusive deal with Britain that
would justify prioritisation of supplies to the United Kingdom.

"AstraZeneca confirmed to us not being under any obligation
to other parties that would impede to complete the fulfilment of
its obligations" to the EU, the Commission spokeswoman said when
asked about Hancock's statements.

Her statement repeated the main points of article 13.1 of
the EU contract with AstraZeneca, under which the company agreed
not to have any contractual obligations that would limit its
ability to meet EU commitments.
A spokesman for AstraZeneca said "the EU supply chain is
overwhelmingly for the EU". He did not comment on whether UK
factories named in the European Union contract were part of the
EU supply chain.

The EU has launched talks with AstraZeneca under a dispute
resolution mechanism included in its contract after the company
said it would aim to deliver only 100 million doses by the end
of June, instead of 300 million committed to in the EU contract.

The spokeswoman said talks with AstraZeneca were about
making sure the company "make(s) full use of its supply lines
and plants which are identified in our contract" to meet its
obligations to the 27-country EU.

Under the EU contract, AstraZeneca committed to supplying
vaccines produced in four European factories, two of which are
in Britain: Oxford Biomedica and Cobra Biologics.

Britain has so far exported no AstraZeneca vaccines to the
EU, despite EU calls for access to doses produced there.

A third factory, run by AstraZeneca's sub-contractor Halix
in the Netherlands, is also listed in the EU contract as a
supplier of vaccines, but Britain says it is entitled to get
doses from there too.

Despite having committed to delivering many more doses to
the EU than to Britain by the end of March, AstraZeneca has so
far shipped more vaccines to the UK than to the 27 EU countries
combined, public data show.

The EU has blamed big shortfalls of AstraZeneca doses for
its slow vaccine roll-out, which is lagging far behind those in
former member Britain and the United States.

Many European countries briefly stopped using the shot
earlier this month while investigating rare cases of blood clots
but resumed when the European Medicines Agency (EMA) said
benefits of AstraZeneca's vaccine outweighed the risks.
(Reporting by Francesco Guarascio @fraguarascio; Editing by
Catherine Evans)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.